BEAM Q2 2024 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-41.5% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$105M-891.1% margin

Net Income

-$91M-773.5% margin

EPS (Diluted)

$-1.11

QoQ Revenue Growth

+58.9%

Cash Flow

Operating Cash Flow

-$83M

Free Cash Flow

-$85M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$407M

Stockholders' Equity

$854M

Cash & Equivalents

$293M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$20M	-41.5%
Gross Profit	$12M	-$77M	+115.2%
Operating Income	-$105M	-$102M	-2.7%
Net Income	-$91M	-$83M	-10.0%